114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
碳青霉烯类耐药菌在危重症患者中的经济负担：一项多中心回顾性队列研究
Authors Jiang W, Feng M, Cao L, Tang Y, Luo X, Dai A, Liu Y, Zhou P, Tang J
Received 23 July 2025
Accepted for publication 19 November 2025
Published 20 December 2025 Volume 2025:18 Pages 6789—6799
DOI https://doi.org/10.2147/IDR.S555843
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Hazrat Bilal
Wenjing Jiang,1,2 Min Feng,3 Li Cao,2 Yan Tang,4 Xianglin Luo,4 Anna Dai,2 Ying Liu,2 Ping Zhou,2 Juan Tang5
1Department of Nursing, Sichuan Vocational College of Health and Rehabilitation, Zigong, People’s Republic of China; 2Department of Hospital Infection Management, Zigong First People’s Hospital, Zigong, 643000, People’s Republic of China; 3Department of Hospital Infection Management, Fushun People’s Hospital, Zigong, 643200, People’s Republic of China; 4Department of Information Technology, Zigong First People’s Hospital, Zigong, 643000, People’s Republic of China; 5Department of Infectious Diseases, Zigong First People’s Hospital, Zigong, 643000, People’s Republic of China
Correspondence: Ping Zhou, Email 1213878640@qq.com Juan Tang, Email 28456465@qq.com
Background: Carbapenem-resistant organisms (CROs) are a growing threat in intensive care units (ICUs) worldwide due to the limited treatment options and high risk of morbidity and mortality. While previous studies have assessed the clinical implications of CROs, few have systematically quantified their economic burden.
Aim: This study aimed to evaluate the economic burden attributable to CROs compared with carbapenem-susceptible organisms (CSOs) among critically ill patients in China.
Methods: We conducted a retrospective cohort study including 7,232 ICU patients from two tertiary hospitals in Western China (2019– 2024). Patients were assigned to either the CRO group or the CSO group and matched using a 1:1 propensity score matching (PSM) approach. ICU length of stay (LOS), hospital LOS, and total hospitalization cost were compared between the two groups, followed by generalized linear models (GLMs) to assess the independent impact of CRO status. Institutional-level opportunity costs were estimated based on excess ICU occupancy.
Results: Among the 7,232 patients, 379 (5.24%) developed CRO, with carbapenem-resistant Acinetobacter baumannii (CRAB) being the predominant pathogen. PSM produced 379 pairs of CRO and CSO patients. The CRO group had significantly longer ICU LOS (median 11.0 vs 5.0 days, P< 0.001), longer hospital LOS (median 24.0 vs 13.0 days, P< 0.001), and higher total hospitalization costs (median CNY 99,549 vs CNY 50,279, P< 0.001) than the CSO group. GLMs showed that CRO independently predicted longer ICU LOS (OR: 2.37; 95% CI: 2.03– 2.76), longer hospital LOS (OR: 1.97; 95% CI: 1.70– 2.27), and higher total hospitalization costs (OR: 1.99; 95% CI: 1.78– 2.23). An estimated 321 hospital admissions and 459 ICU admissions were lost over six years due to excess bed occupancy by CRO patients, resulting in a total institutional financial loss of approximately CNY 134,000 per year.
Conclusion: CROs are associated with substantially increased economic burden in ICU patients. These findings support the implementation of early screening, targeted prevention, and stewardship strategies to mitigate the impact of CROs.
Keywords: carbapenem-resistant organisms, CROs, intensive care units, ICU, economic burden, hospitalization cost, length of stay, propensity score matching, PSM, generalized linear models, GLM
1Department of Nursing, Sichuan Vocational College of Health and Rehabilitation, Zigong, People’s Republic of China; 2Department of Hospital Infection Management, Zigong First People’s Hospital, Zigong, 643000, People’s Republic of China; 3Department of Hospital Infection Management, Fushun People’s Hospital, Zigong, 643200, People’s Republic of China; 4Department of Information Technology, Zigong First People’s Hospital, Zigong, 643000, People’s Republic of China; 5Department of Infectious Diseases, Zigong First People’s Hospital, Zigong, 643000, People’s Republic of China
Correspondence: Ping Zhou, Email 1213878640@qq.com Juan Tang, Email 28456465@qq.com
Background: Carbapenem-resistant organisms (CROs) are a growing threat in intensive care units (ICUs) worldwide due to the limited treatment options and high risk of morbidity and mortality. While previous studies have assessed the clinical implications of CROs, few have systematically quantified their economic burden.
Aim: This study aimed to evaluate the economic burden attributable to CROs compared with carbapenem-susceptible organisms (CSOs) among critically ill patients in China.
Methods: We conducted a retrospective cohort study including 7,232 ICU patients from two tertiary hospitals in Western China (2019– 2024). Patients were assigned to either the CRO group or the CSO group and matched using a 1:1 propensity score matching (PSM) approach. ICU length of stay (LOS), hospital LOS, and total hospitalization cost were compared between the two groups, followed by generalized linear models (GLMs) to assess the independent impact of CRO status. Institutional-level opportunity costs were estimated based on excess ICU occupancy.
Results: Among the 7,232 patients, 379 (5.24%) developed CRO, with carbapenem-resistant Acinetobacter baumannii (CRAB) being the predominant pathogen. PSM produced 379 pairs of CRO and CSO patients. The CRO group had significantly longer ICU LOS (median 11.0 vs 5.0 days, P< 0.001), longer hospital LOS (median 24.0 vs 13.0 days, P< 0.001), and higher total hospitalization costs (median CNY 99,549 vs CNY 50,279, P< 0.001) than the CSO group. GLMs showed that CRO independently predicted longer ICU LOS (OR: 2.37; 95% CI: 2.03– 2.76), longer hospital LOS (OR: 1.97; 95% CI: 1.70– 2.27), and higher total hospitalization costs (OR: 1.99; 95% CI: 1.78– 2.23). An estimated 321 hospital admissions and 459 ICU admissions were lost over six years due to excess bed occupancy by CRO patients, resulting in a total institutional financial loss of approximately CNY 134,000 per year.
Conclusion: CROs are associated with substantially increased economic burden in ICU patients. These findings support the implementation of early screening, targeted prevention, and stewardship strategies to mitigate the impact of CROs.
Keywords: carbapenem-resistant organisms, CROs, intensive care units, ICU, economic burden, hospitalization cost, length of stay, propensity score matching, PSM, generalized linear models, GLM